2 results
Approved WMORecruiting
The objectives of this trial are:1. To define the performance characteristics of FDHT PET in patients with metastasized castrate resistant prostate cancer(mCRPC).(a) To demonstrate the kinetics of displacement of the tracer off of the androgen…
Approved WMOCompleted
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.